Skip to main content
Fig. 3 | Allergy, Asthma & Clinical Immunology

Fig. 3

From: Higher efficacy of rupatadine 20 mg and 10 mg versus placebo in patients with perennial allergic rhinitis: a pooled responder analysis

Fig. 3

Proportion of responders achieving the 75% response in T4NSS or T5SS. Data are expressed as the percentage of patients achieving a 75% reduction in (a) T4NSS or (b) T5SS over 28 days of treatment with rupatadine 10 mg or 20 mg, or placebo. Statistical significance was determined with the Chi-square test. *p < 0.05, **p < 0.01 (rupatadine groups vs placebo). T4NSS Total 4 Nasal Symptom Score, T5SS Total 5 Symptom Score

Back to article page

Allergy, Asthma & Clinical Immunology

ISSN: 1710-1492

Contact us